Bioclassifier
This story has been updated from a previous version to include information about a competitive offering.
By Justin Petrone
The quintet of studies, presented at the American Society of Clinical Oncology annual meeting last week, could help support NanoString's diagnostic ambitions.
ARUP Labs launches PAM50 Breast Cancer Intrinsic Classifier.
NanoString is betting that its test will predict treatment benefit for specific classes of chemotherapies, which will differentiate it from other genomic breast cancer tests on the market.